Abstract
Background Insomnia and substance use disorders (SUD) are common comorbidities of bipolar disorder (BD). Genome-wide association studies (GWAS) have uncovered shared genetic contributions to insomnia and BD as well as SUDs and BD. Using electronic health record (EHR) derived phenotypes (phecodes) and questionnaire data, the authors examined the relationship between insomnia genetic liability and SUDs in BD.
Methods 40,839 participants from the Mayo Clinic Bipolar Disorder Biobank (BD Biobank; n=774) and Mayo Clinic Biobank (n=485 BD cases, n=39,580 controls) were included in the phecode analyses [insomnia, SUD, alcohol use disorder (AUD) and tobacco use disorder (TUD)]. 1789 cases were included in analyses of the BD Biobank questionnaire data, which included information on BD subtype and various SUDs. Logistic regression was used to test for associations between insomnia polygenic risk scores (PRS) and insomnia and SUD phenotypes in BD cases and controls.
Results Insomnia PRS was associated with the insomnia phecode in controls (OR=1.19, p=9.64e-33) but not in BD cases (OR=1, p=0.95). Associations between insomnia PRS and SUD phecodes were significant in BD cases and controls with the effect of the association between insomnia PRS and SUD being stronger in BD cases (interaction p=0.024). In the BD Biobank, the insomnia PRS was associated with increased odds of AUD (OR=1.19, p=4.26e-04), TUD (OR=1.21, p=1.25e-05) and cannabis use disorder (OR=1.16, p=4.19e-03).
Conclusion The effect of genetic predisposition to insomnia on SUD may be stronger in BD cases than controls. This could have clinical treatment implications for individuals with BD and comorbid SUD.
Competing Interest Statement
LMMB has no disclosures to report. BJC has no disclosures to report. AB has no disclosures to report. JASR has no disclosures to report. BPK has no disclosures to report. FRN receives grant support from the National Institute of Mental Health K23 Award (K23MH120503) and from a 2017 NARSAD Young Investigator Award from the Brain and Behavior Research Foundation. He is also the inventor of U.S. Patent and Trademark Office patent No. 10,857,356, transcutaneous spinal cord stimulation for treatment of psychiatric disorders with the University of Cincinnati as assignee. VP has no disclosures to report. GJ has no disclosures to report. TCW has no disclosures to report. MS has no disclosures to report. SLM has been a consultant to or member of the scientific advisory boards of Axsome, Idorsia, Kallyope, Levo, Neurocrine, Novo Nordisk, Otsuka, Sunovion, and Takeda. She has been a principal or coinvestigator on studies sponsored by Neurocrine, Novo Nordisk, Otsuka, Sunovion, Axsome, Marriott Foundation and National Institute of Mental Health. She is also an inventor on United States Patent No. 6,323,236 B2, Use of Sulfamate Derivatives for Treating Impulse Control Disorders, and along with the patent's assignee, University of Cincinnati, Cincinnati, OH, has received payments from Johnson & Johnson, which has exclusive rights under the patent. MAF has received grant support from Assurex Health, Breakthrough Discoveries for Thriving with Bipolar Disorder (BD2), National Heart, Lung, and Blood Institute, National Institute on Alcohol Abuse and Alcoholism, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, and Regents of the University of Michigan. He has received payment from Carnot Laboratories and the American Physician Institute and receives royalties from Chymia LLC. JMB has no disclosures to report.
Funding Statement
This work was supported by the Thomas and Elizabeth Grainger Fund in Bipolar Functional Genomics and Drug Development and National Institute of Mental Health R01 MH121924. The development of the Mayo Clinic Bipolar Disorder Biobank (BD Biobank) was supported by the Marriott Foundation, and the BD Biobank and the Mayo Clinic Biobank (MCB) were supported by the Mayo Clinic Center for Individualized Medicine.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Mayo Clinic gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data in the present study is available through application to each biobank and is unable to be shared otherwise.
